Clinical Case Notes: Propecia-Associated Bilateral Cataract

    Shih Yu Chou, Sung-Shuo Kao, Wen-Ming Hsu
    Image of study
    TLDR Taking Propecia might lead to the development of cataracts.
    In 2004, a case study was conducted on a 43-year-old man who had been taking finasteride (Propecia) for 3 years to treat early stage androgenic alopecia and presented with decreasing vision in both eyes over a period of 3 months. The study suggested that Propecia might be associated with the formation of anterior subcapsular lens opacities, a type of cataract. The patient's cataracts might also be associated with alopecia, as both are ectodermal disorders. However, no dermatological findings were found in the patient or his family. The study concluded that although finasteride, the active ingredient in Propecia, is generally well-tolerated, it can be associated with the development of cataracts. Clinicians were advised to be aware of this potential side effect and report suspected cases to the appropriate regulatory bodies.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 1000+ results

      community Why is everyone not directly advised Dutasteride?

      in Finasteride/Dutasteride  169 upvotes 8 months ago
      Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

      community Why is Kevin Mann (Haircafe) Hated?

      in Chat  62 upvotes 2 years ago
      Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  125 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

    Similar Research

    5 / 1000+ results